Stay updated with breaking news from Nasdaq Cyad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Celyad Oncology SA (NASDAQ:CYAD – Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.69 and traded as high as $0.81. Celyad Oncology shares last traded at $0.75, with a volume of 8,985 shares. Celyad Oncology Stock Down 5.1 […]
Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023Celyad Oncology has received approximately EUR 9.8m in private placement...
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...
MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...
MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...